Browsing category:

New Indication Approval

Known as the prostate cancer powerhouse treatment Zytiga, Abiraterone Acetate has recently become a sales powerhouse for Medivation. The reason for the hype centers on a new indication for this potent anti-cancer drug, specifically as an efficacious pre-chemo treatment. Initial FDA approval for Abiraterone was for post-chemotherapy only. As a post-chemo treatment Zytiga was by[…]

Read More

On September 6, 2013 the FDA approved a new indication for the formidable pancreatic cancer drug Paclitaxel. Known as the brand name Abraxane, which is marketed by Celgene, Paclitaxel is now officially indicated for the first-line treatment of patients with metastatic pancreatic cancer. Paclitaxel will be used in a combination treatment, alongside Gemcitabine, to treat[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service